There should be a significant effect on turnover, but API has...

There should be a significant effect on turnover, but API has signaled as I understand it a similar reduction in discount terms to that when Pfizer left therefore should maintain net profit all other things being equal.

But there wasn't much fat to play with so I do not think any if them are in a position to handle a wholesaler specific problem.

API could be more at risk as sole distributor of Alphapharm products which as one if the main supplier of generics would have one of the major impacts of the PBS reform, particularly has having mature products.

Pfizer has done a good job (for them) of maintaining the supply of the Lipitor molecule..